Please login to the form below
macular degeneration
This page shows the latest macular degeneration news and features for those working in and with pharma, biotech and healthcare.
Astellas signs $962m rare eye disease deal with 4D Molecular Therapeutics
David Kirn, co-founder and chief executive officer of 4DMT, outlined that over 70 patients have been dosed with R100-based product candidates in wet age-related macular degeneration and rare
Latest news
-
Astellas and Cullgen announce protein degrader partnership worth up to $1.9bn
age-related macular degeneration – a major cause of moderate and severe loss of central vision in ageing adults.
-
Astellas to acquire Iveric Bio for approximately $5.9bn
to age-related macular degeneration (AMD).
-
Paris Court of Appeal overturns Novartis and Roche’s €444m anti-competitiveness fine
older and cheaper alternative drug to treat wet age-related macular degeneration (AMD).
-
Roche’s Vabysmo receives EC approval to treat two leading causes of vision loss
Roche has announced the approval of Vabysmo (faricimab) by the European Commission (EC) for the treatment of neovascular age-related macular degeneration (nAMD) and visual impairment due to diabetic macular edema
-
FDA approves Coherus’ Cimerli as biosimilar interchangeable with Lucentis for all five indications
Cimerli is interchangeable for retinal indications including neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy and myopic choroidal neovascularisation.
More from news
Approximately 6 fully matching, plus 131 partially matching documents found.
Latest Intelligence
-
25 Women Leaders in UK Healthcare (part 2)
for advanced dry Age-related Macular Degeneration (AMD).
-
Deal Watch October 2018
RNA‐targeted therapeutic, IONIS‐FB‐LRx targeting Factor. B, for Geographic Atrophy, an advanced form of dry Age-related Macular Degeneration (AMD). ... A phase 2 study in the condition Geographic Atrophy (GA), which is the advanced stage of dry
-
30 Women Leaders in UK Healthcare (part 2)
treatments for age-related macular degeneration (AMD).
-
Working with our healthcare system more closely is vital
to essential treatment, expanding and improving care for people living with a leading cause of vision loss – age-related macular degeneration (AMD).
-
Deal Watch October 2016
330. Ocular Therapeutics (US). Regeneron (US). Licence collaboration. Hydrogel sustained release aflibercept (Eylea) for wet macular degeneration.
More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.
Latest appointments
-
Gyroscope Therapeutics appoints CEO
related macular degeneration.
-
Dr Robert Kim joins Apellis as chief medical officer
While at Genentech he managed the Lucentis phase III clinical programme through to its first approval in wet age related macular degeneration.
-
Life appoints client services director
Kaberry studied oncology, pharmacology and neurobiology, with a final year project on macular degeneration.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Biotech: it's a people business
From Johnson &Johnson’s immunology treatments to Pfizer’s work on a stem cell-based remedy for age-related macular degeneration, pharma companies are quickly realising biotechnology is the future of
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Sanofi and Teva to collaborate on inflammatory bowel disease drug in deal worth $1.5bn
- Eli Lilly to acquire cancer specialist Point Biopharma in deal worth $1.4bn
- Regeneron and Intellia to develop additional gene editing therapies under expanded collaboration
- Novavax’s updated COVID-19 vaccine approved by FDA for emergency use
- Alzheimer’s Research UK awards Cardiff University researchers £387,000
- Actinic keratosis – a common skin condition that can lead to skin cancer
No results were found
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 950 experts delivering world-class...
Latest intelligence
- Actinic keratosis – a common skin condition that can lead to skin cancer
- PMGroup talks to Volker Koscielny, Chief Medical Officer at Almirall, about the importance of remaining vigilant about skin checks, the prevalence of actinic keratosis in the UK and the steps...
- Man vs microbe: the fight against antimicrobial resistance
- How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics...
- Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital
- Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...
